2019 Highlights

January

Opening research and development center for South America in Salto (BR)

Lonza started 2019 by announcing record-breaking full-year 2018 results in a major transformational year

Lonza commenced commercial supply of Portola’s second-generation Andexxa®

Lonza announced the succession of the CEO

February

Opening research and development center for South America in Salto (BR)

Lonza strengthened Pharma Biotech & Nutrition offerings with aligned structure

DuPont Nutrition and Health, and Lonza Specialty Ingredients announced a joint agreement in human milk oligosaccharides

March

Opening research and development center for South America in Salto (BR)

Lonza completed divestment of its Water Care business

Lonza provided adjusted Mid-Term Guidance 2022 to reflect the divestment of its former Water Care business unit

Sheba and Lonza to collaborate on Cocoon platform bringing automated cell-therapy manufacturing to the clinic

April

Opening research and development center for South America in Salto (BR)

Lonza and Chr. Hansen created a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers

May

Opening research and development center for South America in Salto (BR)

Alector opted for Lonza’s Ibex Develop to secure future manufacturing for neurodegeneration therapies

June

Opening research and development center for South America in Salto (BR)

Lonza announced its intention to proceed with a carve-out of its Specialty Ingredients segment to allow the segment to become a global leader in microbial control

Lonza announced an investment in a major expansion of highly potent active pharmaceutical ingredients (HPAPI) capacity at its Visp (CH) site to meet increased market demand

July

Opening research and development center for South America in Salto (BR)

Lonza announced the start of expansion to its bioconjugation facility in Visp (CH), together with the additional antibody drug conjugates (ADCs) produced at the site

Lonza reported continued positive momentum in its core healthcare businesses with organic growth of 6.4% sales and 7.7% CORE EBITDA in H1 2019

August

Opening research and development center for South America in Salto (BR)

Lonza acquired a sterile fill and finish facility from Novartis to complement Pharma Biotech & Nutrition current parenteral drug product offering in Basel (CH)

September

Opening research and development center for South America in Salto (BR)

Celltrion and Lonza signed a contract to manufacture Remsima drug substance

October

Opening research and development center for South America in Salto (BR)

Lonza’s Ibex Solutions in Visp (CH) to support Genmab’s growing clinical portfolio

Mesoblast and Lonza entered into agreement for commercial manufacture of Mesoblast’s potential first United States allogeneic therapy

November

Board announcement – Albert M. Baehny, Chairman of the Board of Directors, took on the additional responsibility of Chief Executive Officer on an ad interim basis. Christoph Mäder appointed as Lead Independent Director

(PDF:) Download section PDF Company Download Center All documents and tables